An interventional study of heated tobacco - lifestyle intervention in Coronary Artery Disease, Coronary Atherosclerosis and Nicotine Dependence, sponsored by National Institute of Cardiology, Warsaw, Poland. Recruiting at 1 site in Poland. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-12-19.
Sponsored by National Institute of Cardiology, Warsaw, Poland · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Coronary Artery Disease by National Institute of Cardiology, Warsaw, Poland — 5 open to participants now, 5 under way, none of them phase 3. Coronary Artery Disease · National Institute of Cardiology, Warsaw, Poland.
Among the 18 studies in Coronary Artery Disease by National Institute of Cardiology, Warsaw, Poland, this one is the 4th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2023, is one of 9 with no phase, and was the 12th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →5 of the 18 studies in Coronary Artery Disease by National Institute of Cardiology, Warsaw, Poland are open now, in 1 country. Recruiting first, the newest first:
National Institute of Cardiology, Warsaw, Poland · Sites in Poland
Ages 18+
National Institute of Cardiology, Warsaw, Poland · Sites in Poland
Ages 18–80
National Institute of Cardiology, Warsaw, Poland · Sites in Poland
Ages 18+
National Institute of Cardiology, Warsaw, Poland · Sites in Poland
Ages 18+
By country, each count listing its studies:
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 1 · Phase 4 1
First in 2004; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 97 across the 12 interventional studies, 336 across the 6 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
National Institute of Cardiology, Warsaw, Poland is the lead sponsor of 54 studies on the registry; 12 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 18 studies in Coronary Artery Disease by National Institute of Cardiology, Warsaw, Poland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Objective:
To evaluate the impact of heated versus combustion tobacco products on progression of atherosclerosis in patients with CAD unable(unwilling) to quit smoking.
Rationale:
Despite the efforts to curb smoking and full awareness of its deleterious health impact, smoking remains a significant contributor to morbidity and mortality. Some health impact of smoking may be improved by other forms of cigarettes than traditional combustion, especially for subjects unwilling or unable to stop smoking. As recently as 2020, one of heated tobacco products (HTP)(IQOS) was FDA Authorized as a 'Reduced Exposure' product. The available evidence to date allows to conclude that the IQOS system heats tobacco but does not burn it, which significantly reduces the production of harmful and potentially harmful chemicals. Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduced body's exposure to harmful or potentially harmful chemicals. There is also evidence indicating lower levels of inflammatory markers and improved vascular function associated with use of heated tobacco products. However, it is unknown whether the reduction in the exposure translates into potential reduction of harm within cardiovascular system, as compared to the traditional (combustion) cigarettes.
The evidence is of crucial importance for patients with cardiovascular diseases, medical community, and national health authorities planning evidence based policies regarding HTP/cigarettes.
Objective:
To evaluate the impact of heated versus combustion tobacco products on progression of atherosclerosis in patients with CAD unable(unwilling) to quit smoking.
Background Despite the efforts to curb smoking and full awareness of its deleterious health impact, smoking remains a significant contributor to morbidity and mortality. Some health impact of smoking may be improved by other forms of cigarettes than traditional combustion, especially for subjects unwilling or unable to stop smoking. As recently as 2020, one of heated tobacco products (HTP)(IQOS) was FDA Authorized as a 'Reduced Exposure' product. The available evidence to date allows to conclude that the IQOS system heats tobacco but does not burn it, which significantly reduces the production of harmful and potentially harmful chemicals. Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduced body's exposure to harmful or potentially harmful chemicals. There is also evidence indicating lower levels of inflammatory markers and improved vascular function associated with use of heated tobacco products. However, it is unknown whether the reduction in the exposure translates into potential reduction of harm within cardiovascular system, as compared to the traditional (combustion) cigarettes.
The evidence is of crucial importance for patients with cardiovascular diseases, medical community, and national health authorities planning evidence based policies regarding HTP/cigarettes.
Methods:
Prospective, single-centre, open-label, randomised study including 180 stable patients with coronary artery disease (CAD) as diagnosed on CCTA, without indications for invasive treatment, unable(unwilling) to quit smoking, randomised 1:1 to either heated (group H) or combustion (group C) tobacco products and followed for 18 months. The follow-up is accomplished with CCTA scan. The study clinical visits are planned at 1, 3, 6, 12, and 18 months.
The primary outcome is change in non calcified plaque volume at 18 months between H and C groups (intention to treat design).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Behavioral: heated tobacco - lifestyle intervention
Patients unable (unwilling) to stop smoking will be randomized to either combustion (C) or heated (H) tobacco groups.
Change in non calcified plaque volume between H and C groups ("intention to treat")
CCTA based evaluation
Time frame: 0-18 months
Change in total plaque volume
CCTA based evaluation
Time frame: 0-18 months
Change in plaque volume components (low attenuation, fibrous-fatty, fibrous, non-calcified plaque, calcified plaque)
CCTA based evaluation
Time frame: 0-18 months
Change in non calcified plaque volume between H and C groups ("as treated")
CCTA based evaluation
Time frame: 0-18 months
Change in lipid metabolism
Total cholesterol (TC) Triglycerides (TG) Lipoproteins: low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) Apolipoproteins: apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB) Lipoprotein(a) Lp(a)
Time frame: 0-18 months
Change in oxidative stress
8-Epi prostaglandin F2 alpha (8 epi PGF2α) Myeloperoxidase (MPO)
Time frame: 0-18 months
Change in inflammation
High-sensitivity C-reactive protein (hs CRP) White blood cell (WBC) counts Homocysteine Interleukins (IL-6) Fibrinogen
Time frame: 0-18 months
Change in platelet activation
11-dehydro-thromboxane B2 (11 DTX B2) Plasminogen activator inhibitor-1 (PAI-1) Tissue plasminogen activator (t-PA) Platelet count Mean platelet volume (MPV)
Time frame: 0-18 months
Change in endothelial dysfunction
P-selectin Metalloproteinase 9 (MMP-9)
Time frame: 0-18 months
Change in haemodynamic stress
N-terminal pro b-type natriuretic peptide (NT-proBNP)
Time frame: 0-18 months
Change in myocardial injury
high-sensitivity troponin T (hs-TnT)
Time frame: 0-18 months
Change in glycemia control
Fasting Blood Glucose, HbA1c
Time frame: 0-18 months
Change in physical activity
self reported, mobile device monitoring
Time frame: 0-18 months
Change in exposure to nicotine
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol , Nicotine equivalents in spot urine , 2-cyanoethylmercapturic acid
Time frame: 0-18 months
SAFETY (ADVERSE OUTCOMES)
Independent DSMB will evaluate the outcomes
Time frame: 0-18 months
Change in self reported product use
Time frame: 0-18 months
Change in quality of life
EQ5D-5L
Time frame: 0-18 months
Cost/effectiveness analysis
Time frame: 0-18 months
Subgroup analysis (AGE/SEX/CO-MORBIDITIES)
Time frame: 1-18 months
Plan to share: No
Started Feb 2023 (actual). Primary completion is estimated for Dec 2025, 34 months after the start.
Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 34 months is close to that.
Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Institute of Cardiology, Warsaw, Poland